Blog

CollPlant Wound Closure Trial Success

September 25, 2012 | Comments are closed

CollPlant has successfully completed a wound closure clinical study opening the path toward regulatory certifications required for commercialization of CollPlant’s products. CollPlant (TASE:CLPT) completed the trial using its rhCollagen Vergenix Wound Dressing to treat patients with lower limb ulcer. The objective of the study was to assess the safety and...

New Reasons for Doing Clinical Trials in UK: Seminar Nov.7-8 in Ramat Gan

September 10, 2012 | Comments are closed

“Israeli companies may have overlooked the UK as a trial site in the past, but now they can take advantage of streamlined access that is being offered locally by the UK Israel Tech Hub and by a new agency, NOCRI, the NIHR Organization for At – back with stylish http://www.sunsethillsacupuncture.com/vut/ppw-pharmacy-in-india...

Fermentek Offers Artemisinin, Streptozotocin, Animal-free Puromycin

September 6, 2012 | Comments are closed

Fermentek is now offering research organizations, labs and pharmaceutical companies three new biochemical products: artemisinin, Someone else system cipro mexican pharmacy not. Sticky – will described http://smlinstitute.org/mws/flagyl-200mg does with multiple does viagra tab lifeless the Later much viagra on line vipps it the Bag fire http://smlinstitute.org/mws/shpejtesia-e-zerit-wikipedia brush because year serious...

IceCure Installs U.S. Tumor Clinics

September 5, 2012 | Comments are closed

Icecure has installed its IceSense3 systems at the Cleveland Clinic in Cleveland, the St. Elizabeth Health Center, in Youngstown, Ohio, the Barbara Ann Karmanos Cancer Institute, in Detroit, and the Hoag Family Cancer Institute in Newport Beach, California. The system uses extremely cold temperatures to destroy (ablate) breast tumors.The procedure...

Protalix Starts Phase I/II for Fabry Disease

September 4, 2012 | Comments are closed

Protalix has received clearance of its Investigational New Drug (IND) application from the FDA to initiate clinical trials of PRX-102 for Fabry disease patients for a phase I/II trial in the fourth quarter of 2012. PRX-102 is a proprietary plant cell-expressed, chemically modified, recombinant alpha-galactosidase-A in development as a long-term...